Listed by the USPTO as DENT, ALANA HARRIS
Tech Center 1600 • Art Units: 1600 1641 1643 1645
This examiner grants 44% of resolved cases
DENT, ALANA HARRIS works in Tech Center 1600 and Art Unit 1600. The profile records 750 resolved cases, a 44.1% allowance rate, and a median of 1362 days to allowance. Interviews show a 32.2% lift in the reported data, making interview practice a material consideration for prosecution before this examiner.
The company list includes Hoffmann-La Roche Inc., The Johns Hopkins University, and THE GENERAL HOSPITAL Corporation. The listed firms are FISH & RICHARDSON P.C. (TC), Casimir Jones, S.C., and KLARQUIST SPARKMAN, LLP. Applicants facing this docket may benefit from early issue identification and deliberate interview preparation, particularly because the allowance rate is below the interview lift figure.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17630046 | DOSAGE AND ADMINISTRATION REGIMEN FOR THE TREATMENT OR PREVENTION OF C5-RELATED DISEASES BY THE USE OF THE ANTI-C5 ANTIBODY CROVALIMAB | Final Rejection | HOFFMANN-LA ROCHE INC. |
| 17630050 | DOSAGE AND ADMINISTRATION REGIMEN FOR THE TREATMENT OR PREVENTION OF C5-RELATED DISEASES BY THE USE OF THE ANTI-C5 ANTIBODY CROVALIMAB | Final Rejection | HOFFMANN-LA ROCHE INC. |
| 18041059 | COMPANION DIAGNOSTIC FOR RTK INHIBITORS | Non-Final OA | The Regents of The University of Michigan |
| 18271579 | COMBINATION THERAPY USING AN ANTI-FUCOSYL-GM1 ANTIBODY | Final Rejection | BRISTOL-MYERS SQUIBB COMPANY |
| 15768853 | POLYMERASE Q AS A TARGET IN HR-DEFICIENT CANCERS | Non-Final OA | DANA-FARBER CANCER INSTITUTE, INC. |
| 16088727 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF CANCERS | Non-Final OA | TORAY INDUSTRIES, INC. |
| 18247144 | INTEGRATED PROTEOMIC BIOMARKERS FOR THE DETECTION OF AGGRESSIVE PROSTATE CANCER | Non-Final OA | THE JOHNS HOPKINS UNIVERSITY |
| 17797676 | CANCER IMMUNOTHERAPY USING TRANSFUSIONS OF ALLOGENEIC, TUMOR-SPECIFIC CD4+ T CELLS | Non-Final OA | The Johns Hopkins University |
| 17101028 | METHODS AND ASSAYS RELATING TO CIRCULATING TUMOR CELLS | Final Rejection | THE GENERAL HOSPITAL CORPORATION |
| 16640942 | METHODS FOR MODULATING THE INTERACTION BETWEEN EWS-FLI1 AND BAF COMPLEXES | Final Rejection | The General Hospital Corporation |
| 18359562 | INTERNALIZING RECEPTOR-DIRECTED BISPECIFIC BINDING AGENT-LIGAND FUSIONS FOR THE DEGRADATION OF TARGET PROTEINS | Non-Final OA | The Regents of the University of California |
| 17916942 | VACCINE PLATFORM FOR THE INDUCTION OF SYSTEMIC IMMUNE RESPONSES | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17615732 | MODIFIED DOSAGE OF SUBCUTANEOUS TOCILIZUMAB FOR RHEUMATOID ARTHRITIS | Non-Final OA | REGENERON PHARMACEUTICALS, INC. |
| 18005802 | Multiple Myeloma Mapping and Uses Thereof | Non-Final OA | The Medical College of Wisconsin, Inc. |
| 17416227 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | Final Rejection | Board of Regents, The University of Texas System |
| 17954477 | PHARMACEUTICAL COMPOSITION | Non-Final OA | Chugai Seiyaku Kabushiki Kaisha |
| 18312719 | SYSTEMS AND METHODS FOR PROMOTING REMYELINATION WITH FACTORS DERIVED FROM UMBILICAL CORD BLOOD MACROPHAGES | Final Rejection | Duke University |
| 17803392 | Fusion Protein Composition(S) Comprising Masked Type I Interferons (IFNa and IFNß) For Use in the Treatment of Cancer and Methods Thereof | Non-Final OA | Nammi Therapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy44.1% of resolved applications examined by Alana Harris Dent were allowed (750 resolved cases), compared with 37.3% across Art Unit 1600 over the last five years.
This examiner's interview lift is +32.2 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Alana Harris Dent took 1,362 days on average from filing to allowance.
Alana Harris Dent examines applications in Art Unit 1600 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
